Prosecution Insights
Last updated: July 17, 2026
Application No. 18/805,099

MOLECULAR SWITCHES

Non-Final OA §DP
Filed
Aug 14, 2024
Priority
Jan 30, 2017 — provisional 62/451,819 +6 more
Examiner
MONSHIPOURI, MARYAM
Art Unit
Tech Center
Assignee
Bioverde Tech LLC
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
764 granted / 967 resolved
+19.0% vs TC avg
Strong +37% interview lift
Without
With
+37.3%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
40 currently pending
Career history
997
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
36.6%
-3.4% vs TC avg
§102
15.3%
-24.7% vs TC avg
§112
15.5%
-24.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 967 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 70-75, 85, 87-88, 92, 94-96, 103, 107-108, 128-131 are under examination on the merits. Claims 1-69, 76-84, 86, 89-91, 93, 97-102, 104-106, 109-127 are canceled. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 70-75, 85, 87-88, 92, 94-96, 103, 107-108, 128-131 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No.11,198,877. Although the claims at issue are not identical, they are not patentably distinct from each other because the scope of said patented claims (generic) embraces the scope of claims in this invention (species). Claims 70-75, 85, 87-88, 92, 94-96, 103, 107-108, 128-131 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No.11,111,496. Although the claims at issue are not identical, they are not patentably distinct from each other because the scope of said patented claims (generic) embraces the scope of claims in this invention (species). Claim 70-75, 85, 87-88, 92, 94-96, 103, 107-108, 128-131 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 2, 6-7, 17, 63, 70-71, 75-77, 128, 131-132, 135 of copending Application No. 18/582,362. Although the claims at issue are not identical, they are not patentably distinct from each other because the scope of claims in said copending application overlaps with the scope of instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. It is noted that applicant has previously attempted to file a terminal disclaimer over said copending application on 5/9/26 and again on 5/13/26. However, as the case record shows (see the paper of 5/27/26), said terminal disclaimer has been disapproved because the power of attorney has not been identified and the necessary fees were required. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARYAM MONSHIPOURI whose telephone number is (571)272-0932. The examiner can normally be reached full-flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie L Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARYAM MONSHIPOURI/Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Aug 14, 2024
Application Filed
Jun 18, 2026
Examiner Interview (Telephonic)
Jul 06, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12674152
POLYPEPTIDES HAVING PECTINASE ACTIVITY, POLYNUCLEOTIDES ENCODING SAME, AND USES THEREOF
2y 11m to grant Granted Jul 07, 2026
Patent 12674186
EFFICIENT PRODUCT CLEAVAGE IN TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES
2y 5m to grant Granted Jul 07, 2026
Patent 12668772
MICROBIAL STEM CELL TECHNOLOGY
3y 6m to grant Granted Jun 30, 2026
Patent 12668834
STRAND DISPLACING AMPLIFICATION ENZYMES
3y 6m to grant Granted Jun 30, 2026
Patent 12662691
HMO PRODUCTION
3y 11m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+37.3%)
2y 1m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 967 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month